多烯磷脂酰胆碱治疗抗结核药物所致肝损伤患者疗效研究

doi:10.3969/j.issn.1672-5069.2021.02.020

Abstract

Abstract: Objective To investigate the therapeutic efficacy of polyene phosphatidylcholine in patients with anti-tuberculosis agents-induced liver injury and its effect on serum heme oxygenase (HO-1), glutathione peroxidase (GSH-Px), and superoxide dismutase (SOD) levels. Methods 78 patients drug-induced liver injury (DILI) during anti-tuberculosis therapy for pulmonary tuberculosis were enrolled in our hospital between March 2018 and March 2019, and were randomly divided into control and observation group with 39 in each, receiving diammonium glycyrrhizinate or polyene phosphatidylcholine orally for 12 weeks. Serum interleukin-6, IL-1β and tumor necrosis factor-α(TNF-ɑ) as well as serum HO-1, GSH-Px and SOD levels were detected.Results At the end of 12 week observation, serum level of alanine aminotransferase (ALT) in the observation group was (28.1 ± 20.5) U/L, which was significantly lower than that in the control group [(59.4 ± 22.7) U/L, P <0.05], and serum level of aspartate aminotransferase (AST) in the observation group was (345.1 ± 17.3) U/L, which was significantly lower than that in the control group [(45.1 ± 17.3) U/L, P <0.05]; serum TNF-ɑ level inthe observation group was (7.4 ± 1.5) pg/mL, which was significantly lower than that in the control group [(10.3 ± 1.8) pg/mL, P <0.05], and serum IL-1β level in the observation group was (13.7 ± 2.1) ng/mL, which was significantly lower than that in the control group [(34.2 ± 4.8) ng / mL, P <0.05]; serum HO-1 level in the observation group was (294.1 ± 16.9) U/L, which was significantly higher than that in the control group [(198.8 ± 17.2) U/L, P <0.05], and serum level of SOD was (544.2 ± 13.3) U/L, which was significantly higher than that in the control group [(421.0 ± 12.8) U/L, P <0.05]. Conclusion The administration of polyene phosphatidylcholine in the treatment of patients with DILI caused by anti-tuberculosis medicine is efficacious, which could significantly increase serum HO-1 and SOD levels, and reduce oxidative stress response, and needs further clinical investigation.

Key words: Drug-induced liver injury, Anti-tuberculosis drugs, Polyene phosphatidylcholine, Diammonium glycyrrhizinate, Heme oxygenase, Glutathione peroxidase, Superoxide dismutase, Therapy

Liu Yunhua, Da Rongfeng, Xu Hubo, et al. Therapeutic efficacy of polyene phosphatidylcholine in patients with anti-tuberculosis agents-induced liver injury[J]. Journal of Practical Hepatology, 2021, 24(2): 228-231.

References

[1] 李奎, 冉仁玉, 江自成, 等. 恩替卡韦治疗肺结核合并HBV携带者抗结核药物所致肝损伤临床初步研究. 实用肝脏病杂志, 2017, 20(5): 606-607.
[2] Yuliwulandari R, Susilowati R W, Wicaksono B D, et al. Nat2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet, 2016, 61(6): 533-537.
[3] Fang Y, Xiao H, Tang S, et al. Clinical features and treatment of drug fever caused by anti-tuberculosis drugs. Clin Respir J, 2016, 10(4): 449-454.
[4] Zhang M, Wu S Q, He J Q. Are genetic variations in glutathione s-transferases involved in anti-tuberculosis drug-induced liver injury a meta-analysis. J Clin Pharm Ther, 2019, 44(6): 844-857.
[5] Jiménez-Arellanes MA, Gutiérrez-Rebolledo GA, Meckes-Fischer M, et al. Medical plant extracts and natural compounds with a hepatoprotective effect against damage caused by antitubercular drugs: a review. Asian Pac J Trop Med, 2016, 9(12): 1141-1149.
[6] 中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版). 中华结核和呼吸杂志, 2019, 10(5): 343-356.
[7] Zhao H, Wang Y, Zhang T, et al. Drug-Induced liver injury from anti-tuberculosis treatment: a retrospective cohort study. Med Sci Monit, 2020, 26(1): 920-923.
[8] 吴秀欣, 张惠勇, 张凯. 抗结核药物所致肝损伤患者血浆MiRNA-4284水平及其临床意义探讨. 实用肝脏病杂志, 2019, 22(2): 212-215.
[9] Saito Z, Kaneko Y, Kinoshita A, et al. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis. BMC Infect Dis, 2016, 16(1): 668-669.
[10] Zazuli Z, Barliana M I, Mulyani U A, et al. Polymorphism of pxr gene associated with the increased risk of drug-induced liver injury in indonesian pulmonary tuberculosis patients. J Clin Pharm Ther, 2015, 40(6): 680-684.
[11] Shang P, Xia Y, Liu F, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (atli) in China. PLoS One, 2016, 6(7):218-219.
[12] Saito N, Yoshii Y, Kaneko Y, et al. Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. BMC Infect Dis, 2019, 19(1): 374-375.
[13] Bhilare N V, Dhaneshwar S S, Mahadik K R, et al. Phenolic acid-tethered isoniazid for abrogation of drug-induced hepatotoxicity: design, synthesis, kinetics and pharmacological evaluation. Drug Deliv Transl Res, 2018, 8(3): 770-779.
[14] 魏明禄, 刘建民, 陈南清, 等. 滋肾益肝方联合多烯磷脂酰胆碱治疗抗结核药物所致急性肝损伤的有效性与安全性研究. 中华中医药学刊, 2018, 36(1): 45-48.
[15] Gafar F, Arifin H, Jurnalis Y D, et al. Antituberculosis drug-induced liver injury in children: incidence and risk factors during the two-month intensive phase of therapy. Pediatr Infect Dis J, 2019, 38(1): 50-53.
[16] 孙勤, 肖和平. 抗结核药物所致肝损伤分子遗传机制的探讨. 中华结核和呼吸杂志, 2018, 41(1): 10-13.
[17] Ngouleun W, Biapa Nya P C, Pieme A C, et al. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/aids-coinfected patients under tuberculosis treatment. Int J Mycobacteriol, 2016, 5(4): 482-488.
[18] Wu ZR, Bai ZT, Sun Y, et al. Protective effects of the bioactive natural product n-trans-caffeoyldopamine on hepatotoxicity induced by isoniazid and rifampicin. Bioorg Med Chem Lett, 2015 , 25(22): 5424-5246.
[19] Njuguna C, Stewart A, Mouton J P, et al. Adverse drug reactions reported to a national HIV & tuberculosis health care worker hotline in south africa: description and prospective follow-up of reports. Drug Saf, 2016, 39(2): 159-69.
[20] Ji G, Huang W, He J, et al. Is anti-tuberculosis drug-induced hepatotoxicity due to a change in pharmacokinetics caused byalterations in antioxidant gene expression and polymorphisms in the nfe2l2 gene. Int J Clin Pharmacol Ther, 2020, 58(2): 67-73.
[21] 魏重操, 刘娜, 邢欣, 等. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析. 实用肝脏病杂志, 2020, 23(1): 46-49.
[22] Zhang H, Jiang T, Yu H, et al. Polyene phosphatidylcholine protects against radiation induced tissue injury without affecting radiotherapeutic efficacy in lung cancer. Am J Cancer Res, 2019, 9(6): 1091-1103.

Therapeutic efficacy of polyene phosphatidylcholine in patients with anti-tuberculosis agents-induced liver injury

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yuan Pingge, Chen Wenwen. Insights to new medicine development for treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 305-307.
[2]	Xu Wenting, Zhang Jihong, Wei Dongjue, et al. Efficacy of tenofovir rescue therapy for patients with chronic hepatitis B and rtM204 mutation [J]. Journal of Practical Hepatology, 2021, 24(3): 335-338.
[3]	Wang Xue, Qu Falin, Qi Weili, et al. Balance of peripheral blood Treg cells/ Th17 cells in patients with chronic hepatitis B and its impact on response to telbivudine treatment [J]. Journal of Practical Hepatology, 2021, 24(3): 339-342.
[4]	Qi Mei, Zhang Ruijin, Tian Shuping, et al. Impacting factors in response to immunosuppressive therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 371-374.
[5]	Huang Chunyang, Chen Jie, Zhang Xiaodan, et al. Serum ALT/ALP ratio changes and histopathological features of patients with drug-induced liver injury acute hepatocellular type [J]. Journal of Practical Hepatology, 2021, 24(3): 379-382.
[6]	Wang Yunqiang, Wang Liping, Huang Dongmei, et al. Changes ofportal hemodynamics in patients with hepatitis B cirrhosis after transjugular intrahepatic portosystemic stent-shunt [J]. Journal of Practical Hepatology, 2021, 24(3): 399-402.
[7]	Wu Chang, Zhang Yuan’an, Peng Chunfen. Efficacy of endoscopic variceal ligation and carvedilol maintenance in the treatment of patients with liver cirrhosis and esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2021, 24(3): 403-406.
[8]	Zhao Kai, Xue Jinfeng, Xue Pengfei, et al. Application of Viatorr covered stent in TIPS for treatment of cirrhotics with portal hypertension [J]. Journal of Practical Hepatology, 2021, 24(3): 419-422.
[9]	Feng Hao, Lyu Haitao, Wang Ziwei, et al. Efficacy of one-step and step-by-steplaparoscopic cholecystectomy in the treatment of patients with gallbladder stones and common bile duct stones [J]. Journal of Practical Hepatology, 2021, 24(3): 435-438.
[10]	Zhang Xinhe, Tian Haoyu, Li Yiling. Current therapeutic strategy for patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2021, 24(3): 453-456.
[11]	Guo Li, Song Yuanzong. Clinical management of pediatric patients with Alagille syndrome [J]. Journal of Practical Hepatology, 2021, 24(2): 160-163.
[12]	He Yufeng, Zhong Xiaoni, Huang Jianrong, et al. Short-term efficacy of tenofovir dipivoxil and entecavir in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(2): 200-203.
[13]	Nie Liu, Peng Hanming, Liao Dongliang. Combination of ursodeoxycholic acid and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(2): 224-227.
[14]	Lin Cheng, Wang Tongbiao, Li Yueyong, et al. Short-term efficacy of magnesium isoglycyrrhizinate and adenosylmethionine butanedisulfonate combination in treatment of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(2): 232-235.
[15]	Zhang Yan, Xia Wenfang, Jin Jin, et al. Short-term observation ofglicladine and insulin aspart 50 in the treatment of patients with non-alcoholic fatty liver diseases and hepatogenic diabetes [J]. Journal of Practical Hepatology, 2021, 24(2): 240-243.